|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
651601210[E00200251]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1g(2005.08.01)(ÇöÀç¾à°¡)
\50 ¿ø/1g(2004.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¾ËÄÚ¿Ã ³¿»õ°¡ ³ª´Â ¹é»ö ³»Áö À¯¹é»öÀÇ ¹ÝÅõ¸í °ÖÁ¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
80g |
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
ÇÁ·Î°Ô½ºÅ×·Ð °áÇÌÀ¸·Î ÀÎÇÑ ºÒÀÓ ¿©¼ºÀÇ ART(Assisted Reproductive Technique)ÀÇ ÇѺκÐÀ¸·Î¼ ÇÁ·Î°Ô½ºÅ×·ÐÀÇ º¸Ãæ ¹× ´ëü
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:218502CCM ¿¡ µû¸¥ ½É»çÁöħ¿¶÷]
ART(Assisted Reproductive Technique) : ÀÌ ¾àÀ» 90mgÀÇ ¿ë·®À¸·Î ÇÁ·Î°Ô½ºÅ×·Ð º¸ÃæÀÌ ÇÊ¿äÇÑ ¿©¼º¿¡°Ô 1ÀÏ 1ȸ Åõ¿©ÇÕ´Ï´Ù. ÇÁ·Î°Ô½ºÅ×·Ð ´ëü¿ä¹ýÀÌ ÇÊ¿äÇÑ ºÎºÐÀû ¶Ç´Â ¿ÏÀüÇÑ ³¼ÒºÎÀüÀÇ ¿©¼º¿¡´Â 1ÀÏ 2ȸ Åõ¿©ÇÕ´Ï´Ù. ÀÓ½ÅÀÌ µÇ¸é ŹÝÀÌ ÀÚÀ²¼ºÀ» ȹµæÇÒ ¶§±îÁö 10-12ÁÖ°£ Åõ¿©ÇÕ´Ï´Ù.
|
| ±Ý±â |
1) ÀÌ ¾à(ÁÖ¼ººÐÀÎ ÇÁ·Î°Ô½ºÅ×·Ð ¶Ç´Â ºÎÇüÁ¦)¿¡ °ú¹Î¼ºÀΠȯÀÚ
2) Áø´ÜµÇÁö ¾ÊÀº Áú ÃâÇ÷
3) °£ ºÎÀü ¶Ç´Â Áúȯ
4) ±âÁö ¶Ç´Â ÀǽɵǴ À¯¾Ï ¶Ç´Â »ý½Ä±âÀÇ ¾Ç¼ºÁ¾¾ç
5) ºÒ¿ÏÀüÀ¯»ê
6) Ç÷Àü¼ºÁ¤¸Æ¿°, Ç÷Àü»öÀüÁõ ȯÀÚ ¶Ç´Â È£¸£¸ó °ü·ÃÇ÷Àü¼ºÁ¤¸Æ¿°, Ç÷Àü»öÀüÁõÀÇ ±â¿Õ·ÂÀÌ Àִ ȯÀÚ.
7) Æ÷¸£ÇǸ°Áõ ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
1) ÇÁ·Î°Ô½ºÅ×·Ð 8% °Ö 1ÀÏ 2ȸ Åõ¿© : ART¿¡ ³¼ÒºÎÀüÀ¸·Î ÀÎÇØ ³¸ð¼¼Æ÷ °ø¿© ¹ÞÀº ȯÀÚ¿¡¼ 5% ÀÌ»ó ÀϾ´ø ÀÌ»ó¹ÝÀÀ
(1) Àü½Å : ºÎÁ¾, °æ·Ã, ÅëÁõ
(2) ÁßÃß ¹× ¸»ÃʽŰæ°è : ÇöÈÆ, µÎÅë
(3) ¼Òȱâ°è : ¿À½É
(4) ¿©¼º»ý½Ä±â°è: À¯¹æÅë, À½ºÎ ¸ð´Ò¸®¾ÆÁõ, ÁúºÐºñ¹°
(5) ÇǺΠ¹× ¿¬Á¶Á÷: À½ºÎ ¼Ò¾çÁõ
2) ÇÁ·Î°Ô½ºÅ×·Ð 8% °Ö 1ÀÏ 1ȸ Åõ¿©: ü¿Ü¼öÁ¤ °úÁ¤ Áß È²Ã¼±â ÁöÁö¸ñÀûÀ¸·Î »ç¿ëÇÑȯÀÚ¿¡¼ 5% ÀÌ»ó ÀϾ´ø ÀÌ»ó¹ÝÀÀ
(1) Àü½Å : º¹Åë, ȸÀ½ºÎ ÅëÁõ
(2) ÁßÃß ¹× ¸»ÃʽŰæ°è : µÎÅë
(3) ¼Òȱâ°è : º¯ºñ, ¼³»ç, ¿À½É, ±¸Åä
(4) ±Ù°ñ°Ý°è : °üÀýÅë
(5) Á¤½Å½Å°æ°è :¿ì¿ï, ¼º¿å°¨¼Ò, ±äÀå, Á¹À½
(6) ¿©¼º»ý½Ä±â°è: À¯¹æÈ®´ë, ¼º±³ ºÒÄèÁõ
(7) ºñ´¢±â°è: ¾ß´¢Áõ
3) ÇÁ·Î°Ô½ºÅ×·Ð 4% °Ö ¹× 8% °Ö 2ÀÏ 1ȸ, ÃÑ 6ȸ Åõ¿© : ¿ù°æÁÖ±â ÀÌ»ó¿¡ ¿¡½ºÆ®·Î°Õ°ú º´¿ëÇÑ ÀÓ»ó½ÃÇè¿¡¼ 5%ÀÌ»óÀÇ È¯ÀÚ¿¡¼ ÀϾ´ø ÀÌ»ó¹ÝÀÀ
(1) Àü½Å : º¹Åë, ½Ä¿åÇ×Áø, ºÎÁ¾, °æ·Ã, ÇÇ·Î
(2) ÁßÃß ¹× ¸»ÃʽŰæ°è : µÎÅë
(3) ¼Òȱâ°è : ¿À½É
(4) ±Ù°ñ°Ý°è : ¿äÅë, ±ÙÀ°Åë
(5) Á¤½Å½Å°æ°è :¿ì¿ï, °¨Á¤Àû ºÒ¾È, ¼ö¸éÀå¾Ö
(6) ¿©¼º»ý½Ä±â°è: Áú ºÐºñ¹°
(7) ³»¼º±âÀü : »ó±âµµ°¨¿°
(8) ÇǺΠ¹× ¿¬Á¶Á÷ : ¿ÜÀ½ºÎ ¼Ò¾çÁõ
4) ART ¹× ¿ù°æÁÖ±â ÀÌ»ó ȯÀÚ¿¡¼ 5% ¹Ì¸¸ º¸°íµÇ¾ú´øÀÌ»ó¹ÝÀÀ
(1) ÀÚÀ²½Å°æ°è :±¸°°ÇÁ¶, ¹ßÇÑ Áõ°¡
(2) Àü½Å : ºñÁ¤»óÀû¿ïÀ½, ¾Ë·¯Áö ¹ÝÀÀ, ¾Ë·¯Áö, ½Ä¿åºÎÁø, ¹«·ÂÁõ, ºÎÁ¾, ¾È¸éºÎÁ¾, ¹ß¿, Á¶È«, µ¶°¨À¯»çÁõÈıº, ¼öºÐÀú·ù, ¾È±¸°ÇÁ¶Áõ.
(3) ½ÉÇ÷°ü°è : ½Ç½Å
(4) ÁßÃß ¹× ¸»ÃʽŰæ°è : ÆíµÎÅë, ÁøÀü
(5) ¼Òȱâ°è : ¼ÒȺҷ®, Æ®¸², °íâ, À§¿°, Ä¡Åë
(6) ´ë»ç : ±¸°¥
(7) °ñ°Ý±Ù°è : ÇÏÁö°æ·Ã, ÇÏÁöµ¿Åë, °ñ°Ý µ¿Åë
(8) ½Å»ý¹° : ¾ç¼º³¶Á¾
(9) Ç÷¼ÒÆÇ, ÃâÇ÷°úÁöÇ÷: ÀÚ¹Ý
(10) Á¤½Å½Å°æ°è :°ø°ÝÀû ¹ÝÀÀ, °Ç¸ÁÁõ, ºÒ¸é
(11) ÀûÇ÷±¸: ºóÇ÷
(12) ¿©¼º»ý½Ä±â°è: ¹«¿ù°æ, ¿ù°æÀü ±äÀå, Áú°ÇÁ¶
(13) ³»¼º ±âÀü :°¨¿°, Àεο°, ºÎºñ°¿°, ¿ä·Î°¨¿°
(14) È£Èí±â°è : õ½Ä, ¹«È£Èí, °úÈ£Èí, ºñ¿°
(15) ÇǺΠ¹× ¿¬Á¶Á÷ : ¿©µå¸§, ¼Ò¾çÁõ, È«¹Ý, Áö·ç, ÇǺκ¯»ö, ÇǺÎÀÌ»ó, ´ã¸¶Áø.
(16) ºñ´¢±â°è : ¹æ±¤¿°, ¹è´¢°ï¶õ, ºó´¢
(17) ½Ã°¢Àå¾Ö : °á¸·¿°
5) ±¹³» ½ÃÆÇ ÈÄ »ç¿ë¼ºÀûÁ¶»ç°á°ú
±¹³»¿¡¼ Àç½É»ç¸¦ À§ÇÏ¿© 6³â µ¿¾È 733¸íÀ» ´ë»óÀ¸·Î ½Ç½ÃÇÑ ½ÃÆÇ ÈÄ »ç¿ë¼ºÀûÁ¶»ç°á°ú ÀÌ»ó¹ÝÀÀÀǹßÇöÁõ·ÊÀ²Àº Àΰú°ü°è¿Í »ó°ü¾øÀÌ 1.23%(9·Ê/733·Ê)·Î º¸°íµÇ¾ú°í, ÀÌ Áß ÀÌ ¾à°ú °ü·ÃÀÌ ÀÖ´Â °ÍÀ¸·Î º¸°íµÈ °ÍÀº 0.68%(5·Ê/733·Ê)ÀÌ´Ù. °¡·Á¿òÁõ 2°Ç, ÁúÀÇÅëÁõ, ºÎÁ¾, ¹ßÁøÀÌ °¢1°Ç ¾¿ ³ªÅ¸³µ°í, ½ÃÆÇÀü ÀÓ»ó½ÃÇè¿¡¼ ³ªÅ¸³ªÁö ¾Ê¾Ò´ø »õ·Î¿î ÀÌ»ó¹ÝÀÀÀ¸·Î ½ÖµÕÀ̼ҽÇ(vanishing twin), ¿ù°æ°£ ÃâÇ÷ÀÌ 1°Ç¾¿ º¸°íµÇ¾ú´Ù. ±×·¯³ª »õ·Î¿î ÀÌ»ó¹ÝÀÀÀÌ ÀÌ ¾àÀÇ Åõ¿©¿Í Àΰú°ü°è°¡ ÀÖ´ÂÁö ¿©ºÎ´Â È®½ÇÇÏÁö ¾Ê´Ù.
|
| »óÈ£ÀÛ¿ë |
ÀÌ ¾àÀ¸·Î ÀÎÇÑ »óÈ£ÀÛ¿ëÀº Æò°¡µÈ ¹Ù ¾ø´Ù.
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Progesterone¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Progesterone¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like Progesterone will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge.
|
| Pharmacology |
Progesterone¿¡ ´ëÇÑ Pharmacology Á¤º¸ Progesterone is a progestin or a synthetic form of the naturally occurring female sex hormone, progesterone. In a woman's normal menstrual cycle, an egg matures and is released from the ovaries (ovulation). The ovary then produces progesterone, preventing the release of further eggs and priming the lining of the womb for a possible pregnancy. If pregnancy occurs, progesterone levels in the body remain high, maintaining the womb lining. If pregnancy does not occur, progesterone levels in the body fall, resulting in a menstrual period. Progesterone tricks the body processes into thinking that ovulation has already occurred, by maintaining high levels of the synthetic progesterone. This prevents the release of eggs from the ovaries.
|
| Protein Binding |
Progesterone¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 96%-99%
|
| Half-life |
Progesterone¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 34.8-55.13 hours
|
| Absorption |
Progesterone¿¡ ´ëÇÑ Absorption Á¤º¸ Progesterone absorption is prolonged with an absorption half-life of approximately 25-50 hours.
|
| Pharmacokinetics |
ProgesteroneÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : °æ±¸, ±ÙÀ°ÁÖ»ç : ½Å¼ÓÇÏ°Ô Èí¼öµÈ´Ù.
- »ýü³»ÀÌ¿ë·ü : °æ±¸ : ÃÊȸÅë°úÈ¿°ú°¡ Ä¿¼ »ýü³»ÀÌ¿ë·üÀº ³·´Ù.
- ´ë»ç : °£¿¡¼ ½Å¼ÓÇÏ°Ô ´ë»çµÈ´Ù.
- ¹Ý°¨±â : 5ºÐ
- ¼Ò½Ç : ´ë»çü·Î¼ ½Å¹è¼³µÈ´Ù.
|
| Biotransformation |
Progesterone¿¡ ´ëÇÑ Biotransformation Á¤º¸ Progesterone is metabolized primarily by the liver largely to pregnanediols and pregnanolones.
|
| Toxicity |
Progesterone¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Progesterone¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸] Progesterone¿¡ ´ëÇÑ P450 table
SUBSTRATES
CYP 2C19
Proton Pump Inhibitors:
omeprazole
lansoprazole
pantoprazole
rabeprazole
Anti-epileptics:
diazepam
phenytoin
phenobarbitone
amitriptyline
clomipramine
clopidogrel
cyclophosphamide
**progesterone**
INHIBITORS
CYP 2C19
fluoxetine
fluvoxamine
ketoconazole
lansoprazole
omeprazole
ticlopidine
INDUCERS
CYP 2C19
N/A
|
| Drug Target |
[Drug Target]
|
| Description |
Progesterone¿¡ ´ëÇÑ Description Á¤º¸ The major progestational steroid that is secreted primarily by the corpus luteum and the placenta. Progesterone acts on the uterus, the mammary glands and the brain. It is required in embryo implantation; pregnancy maintenance, and the development of mammary tissue for milk production. Progesterone, converted from pregnenolone, also serves as an intermediate in the biosynthesis of gonadal steroid hormones and adrenal corticosteroids. [PubChem]
|
| Dosage Form |
Progesterone¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralGel IntravaginalLiquid Intramuscular
|
| Drug Category |
Progesterone¿¡ ´ëÇÑ Drug_Category Á¤º¸ ContraceptivesProgestins
|
| Smiles String Canonical |
Progesterone¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C
|
| Smiles String Isomeric |
Progesterone¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
|
| InChI Identifier |
Progesterone¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1
|
| Chemical IUPAC Name |
Progesterone¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
|
| Drug-Induced Toxicity Related Proteins |
PROGESTERONE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Mitogen-activated protein kinase Drug:progesterone Toxicity:progesterone-induced oocyte maturation . [¹Ù·Î°¡±â] Replated Protein:Angiotensinogen Drug:progesterone Toxicity:rogesterone-induced luteinizing hormone surge. [¹Ù·Î°¡±â] Replated Protein:Retinol-binding protein, cellular Drug:progesterone Toxicity:increase luteal cell progesterone accumulation. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2015-01-16
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|